JO2178B1 - Treatment of invasive diseases, using selected anti-PAR materials - Google Patents

Treatment of invasive diseases, using selected anti-PAR materials

Info

Publication number
JO2178B1
JO2178B1 JO2000172A JOP20000172A JO2178B1 JO 2178 B1 JO2178 B1 JO 2178B1 JO 2000172 A JO2000172 A JO 2000172A JO P20000172 A JOP20000172 A JO P20000172A JO 2178 B1 JO2178 B1 JO 2178B1
Authority
JO
Jordan
Prior art keywords
emphysema
treatment
rar
agonists
retinoid antagonists
Prior art date
Application number
JO2000172A
Other languages
Arabic (ar)
English (en)
Inventor
نايت بيلوني بولا
كلوز ميشيل
Original Assignee
اف . هوفمان لاروش ايه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اف . هوفمان لاروش ايه جي filed Critical اف . هوفمان لاروش ايه جي
Application granted granted Critical
Publication of JO2178B1 publication Critical patent/JO2178B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JO2000172A 1999-10-19 2000-10-12 Treatment of invasive diseases, using selected anti-PAR materials JO2178B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19

Publications (1)

Publication Number Publication Date
JO2178B1 true JO2178B1 (en) 2003-04-23

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2000172A JO2178B1 (en) 1999-10-19 2000-10-12 Treatment of invasive diseases, using selected anti-PAR materials

Country Status (33)

Country Link
US (1) US6300350B1 (enExample)
EP (1) EP1225878B1 (enExample)
JP (2) JP4074458B2 (enExample)
KR (1) KR100485581B1 (enExample)
CN (1) CN1201730C (enExample)
AR (1) AR029648A1 (enExample)
AT (1) ATE344661T1 (enExample)
AU (1) AU777325B2 (enExample)
BR (1) BR0015225A (enExample)
CA (1) CA2387844C (enExample)
CY (1) CY1105941T1 (enExample)
CZ (1) CZ20021657A3 (enExample)
DE (1) DE60031790T2 (enExample)
DK (1) DK1225878T3 (enExample)
ES (1) ES2274810T3 (enExample)
HR (1) HRP20020329A2 (enExample)
HU (1) HUP0203295A3 (enExample)
IL (1) IL149151A0 (enExample)
JO (1) JO2178B1 (enExample)
MA (1) MA26835A1 (enExample)
MX (1) MXPA02003843A (enExample)
MY (1) MY129001A (enExample)
NO (1) NO328738B1 (enExample)
NZ (1) NZ518118A (enExample)
PE (1) PE20010678A1 (enExample)
PL (1) PL357499A1 (enExample)
PT (1) PT1225878E (enExample)
RS (1) RS50165B (enExample)
RU (1) RU2257383C2 (enExample)
TR (1) TR200201071T2 (enExample)
TW (1) TWI288639B (enExample)
WO (1) WO2001030326A1 (enExample)
ZA (1) ZA200202576B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
CA2460693C (en) * 2001-09-18 2010-12-07 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
RU2303027C2 (ru) 2001-09-18 2007-07-20 Ф.Хоффманн-Ля Рош Аг Производные замещенной мочевины, фармацевтическая композиция и лекарственное средство на их основе, обладающие ретиноидной активностью
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
ES2481167T3 (es) 2003-08-22 2014-07-29 Dupont Nutrition Biosciences Aps Composición que comprende una bacteriocina y un extracto de una planta de la familia Labiatae
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
EP2089017A2 (en) * 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
US9789074B2 (en) 2010-09-01 2017-10-17 Thomas Jefferson University Composition and method for muscle repair and regeneration
CN103732231B (zh) 2011-06-24 2020-04-10 格里生物公司 炎性病症的预防和治疗
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2736332A4 (en) * 2011-07-29 2015-03-18 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
NZ709197A (en) 2012-12-17 2020-06-26 Parion Sciences Inc 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
WO2015026990A2 (en) 2013-08-20 2015-02-26 University Of Washington Through Its Center For Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase
US10500232B2 (en) 2013-08-26 2019-12-10 The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618590B2 (en) * 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
AU677428B2 (en) * 1993-08-19 1997-04-24 Janssen Pharmaceutica N.V. Vasoconstrictive dihydrobenzopyran derivatives
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
DE69604713T2 (de) * 1995-02-24 2000-06-21 F. Hoffmann-La Roche Ag, Basel Retinoide
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
WO1999024024A2 (en) * 1997-11-12 1999-05-20 F. Hoffmann-La Roche Ag Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
WO2000061182A2 (en) 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
EP1206436B1 (en) * 1999-08-02 2004-10-13 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
TR200201071T2 (tr) 2002-08-21
DE60031790T2 (de) 2007-09-20
US6300350B1 (en) 2001-10-09
HRP20020329A2 (en) 2004-04-30
CZ20021657A3 (cs) 2002-10-16
JP4850791B2 (ja) 2012-01-11
BR0015225A (pt) 2002-07-16
CN1382042A (zh) 2002-11-27
KR100485581B1 (ko) 2005-04-27
WO2001030326A1 (en) 2001-05-03
PT1225878E (pt) 2007-01-31
PE20010678A1 (es) 2001-07-04
NO20021823L (no) 2002-04-18
IL149151A0 (en) 2002-11-10
CA2387844C (en) 2009-04-14
AR029648A1 (es) 2003-07-10
TWI288639B (en) 2007-10-21
RS50165B (sr) 2009-05-06
NO20021823D0 (no) 2002-04-18
PL357499A1 (pl) 2004-07-26
JP2003512418A (ja) 2003-04-02
JP4074458B2 (ja) 2008-04-09
HUP0203295A2 (hu) 2003-01-28
MA26835A1 (fr) 2004-12-20
NO328738B1 (no) 2010-05-03
NZ518118A (en) 2004-02-27
MY129001A (en) 2007-03-30
CA2387844A1 (en) 2001-05-03
ES2274810T3 (es) 2007-06-01
AU777325B2 (en) 2004-10-14
MXPA02003843A (es) 2002-09-30
JP2007302689A (ja) 2007-11-22
ATE344661T1 (de) 2006-11-15
ZA200202576B (en) 2003-09-23
HK1051002A1 (zh) 2003-07-18
AU1137401A (en) 2001-05-08
RU2257383C2 (ru) 2005-07-27
DK1225878T3 (da) 2007-03-05
HUP0203295A3 (en) 2003-04-28
EP1225878B1 (en) 2006-11-08
EP1225878A1 (en) 2002-07-31
CN1201730C (zh) 2005-05-18
KR20020043640A (ko) 2002-06-10
DE60031790D1 (de) 2006-12-21
YU29002A (sh) 2005-06-10
CY1105941T1 (el) 2011-04-06

Similar Documents

Publication Publication Date Title
JO2178B1 (en) Treatment of invasive diseases, using selected anti-PAR materials
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
AU2003234231A1 (en) New polyarylates for drug delivery and tissue engineering
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
MY125978A (en) Admantane derivatives
AU2003245282A1 (en) Stent coatings with sustained drug release rate
ME00578A (en) Use of gastrointestinal lipase inhibitors
TR200100054T2 (tr) Paroksetin metansülfonat
IL162669A0 (en) Antichlinergic agents, method for producing the same and use thereof as medicaments
EP1745797A3 (en) Vascularization inhibitors
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
BG108516A (en) Pharmaceutical formulation
DE69531098D1 (de) Piperidine und pyrrolidine
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
AU2003297199A8 (en) Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
MY146794A (en) Use of an alpha-2-delta ligand for the treatment of luts
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
IL165213A0 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilizationmedicament or diagnostic agent and medicament containing same
MY136880A (en) Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
IT1321290B1 (it) Metodo per la sterilizzazione di condotti di alimentazione di fluidoa strumenti medici, ed in particolare odontoiatrici.